
COVID-19: Moderna reports promising interim results
On Monday, Moderna Inc. announced that two 100µg shots of its mRNA COVID-19 vaccine candidate mRNA-1273 showed an efficacy of 94,5%, according to an...

Valneva in talks with EU about 60 million vaccine doses
VLA2001 is currently the only inactivated vaccine candidate in clinical trials against COVID-19 in Europe. The vaccine candidate entered Phase I/II...

Siemens launches COVID-19 antigen lateral flow test
As testing capacities for the SARS-CoV-2 gold standard RT-PCR are going to be exhausted upon the looming second wave of infections with the novel...

How microplastic particles get into the body
Microplastic particles exposed to freshwater or saltwater environments for several weeks are about ten times more likely than pristine particles to...

Germany first EU country to launch COVID-19 therapy offensive?
"Besides protection by masks, social distancing etc, rapid diagnostic testing, and COVID-19 vaccines, we are now establishing a fourth pillar of...

EU approves second COVID-19 vaccine
The EU has secured a total of 160 million doses of mRNA-1273 from the US-American manufacturer Moderna, which has outsourced production sites on the...

Angelini Pharma to take over Arvelle Therapeutics
Under the terms of the agreement, Angelini Pharma will acquire Arvelle Therapeutics in an all-cash transaction for a total consideration of up to...